7,597.93

+17.86

+0.24%

52,246.95

+476.64

+0.92%

25,458.70

+21.70

+0.09%

2,828.31

+16.47

+0.59%

4.8820

-0.0470

-0.95%

19.67

+0.25

+1.29%

3,969.40

+70.50

+1.81%

76,835.27

-928.29

-1.19%

Crude Oil Dec 26

96.03

-8.09

-7.77%

US Private Equity

10,850.63

-82.20

-0.75%

Paris - Delayed Quote EUR

ABIONYX Pharma SA (ABNX.PA)

1.5680 -0.0480 (-2.97%)

At close: 5:35:13 PM GMT+1

Loading Chart for ABNX.PA

Chart Range Bar

Interval:

In partnership with ChartIQ

ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization

ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

ABIONYX Pharma and OLON Enter Into Strategic Manufacturing Partnership to Prepare CER-001 Biologic for Regulatory Approval and Commercial Supply

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

ABIONYX Pharma Announces the Settlement of an Anticipated Amortization Payment in Accordance With the Terms of Its Bonds Financing Agreement

ABIONYX Pharma: Half Year Results 2026

ABIONYX Pharma: Half Year Results 2026

ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million

ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million

Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Mobilize your Website

View Site in Mobile | Classic

Share by: